SCHEMBL6360919

SCHEMBL6360919

CCC(O)C(O)c1cncc(N2CCN(C)CC2)c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
HRH4 Q9H3N8 1/20 0.39
CHEK1 O14757 2/20 0.38
HTR3A P46098 1/20 0.37
CYP11B2 P19099 1/20 0.37
KDM4E B2RXH2 2/20 0.36
ADRA2C P18825 3/20 0.36
ADRA2A P08913 1/20 0.35
MAPT P10636 2/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
GFER P55789 1/20 0.35
KMT2A Q03164 1/20 0.35
PTK2B Q14289 1/20 0.35
ESR2 Q92731 1/20 0.35
RPS6KA3 P51812 1/20 0.34
RPS6KA2 Q15349 1/20 0.34
RPS6KA1 Q15418 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6351770 0.89 NOS3 (0.38) NOS3NOS1HRH4CHEK1HTR3A
SCHEMBL6348918 0.87 HRH4 (0.38) NOS3NOS1HRH4CHEK1HTR3A
SCHEMBL6352287 0.85 CHRNB2 (0.49)
SCHEMBL6349942 0.85 CHKA (0.42) NOS3NOS1HRH4CHEK1CYP11B2
SCHEMBL6357838 0.84 HRH4 (0.41) NOS3NOS1HRH4CHEK1HTR3A
SCHEMBL6360127 0.83 CHKA (0.40) NOS3NOS1HRH4CYP11B2
SCHEMBL13436500 0.77 HRH4 (0.44) NOS3NOS1HRH4CHEK1HTR3A
SCHEMBL6348863 0.75 CHRNB2 (0.47)
SCHEMBL6359730 0.73 CHRNB2 (0.45) HRH4
SCHEMBL13436278 0.72 CCR6 (0.46) NOS3NOS1HRH4HTR3ACYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6897219-B2 Heteroaryl diazacycloalkanes, their preparation and use NEUROSEARCH A/S (DK) 2005-05-24 US disclosed
US-6825189-B1 TREATING WITHDRAWAL SYMPTOMS CAUSED BY SMOKING CESSATION NEUROSEARCH A/S (DK) 2004-11-30 US disclosed
EP-1027336-B1 HETEROARYL DIAZACYCLOALKANES AS CHOLINERGIC LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH AS (DK) 2004-10-06 EP disclosed
US-20040072823-A1 Heteroaryl diazacycloalkanes, their preparation and use; NEUROSEARCH A/S 2004-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072823-A1 Heteroaryl diazacycloalkanes, their preparation and use; OGFR, CBR3, OGFRL1 NOS3 308/4885NOS1 1073/4885HRH4 1693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.